News & Analysis on Clinical Trial Services & Contract Research And Development
Postponement of this year’s CPhI and P-MEC India events for “security reasons” may be only the first impact of last week’s Mumbai terror attacks on the country’s outsourcing industry, according to PwC’s life sciences head Sujay Shetty.
Penwest Pharmaceutical’s TIMERx drug delivery technology is to be used to develop one of Otsuka Pharmaceutical’s compounds under a new deal.
Althea Technologies has signed a contract manufacturing deal, under which it will produce Bio-Path’s lead novel therapeutic drug for upcoming clinical trials.
Competition commissioner Neelie Kroes said that some drugmakers operating in the EU are deliberately stalling the introduction of generics, costing European patients around €3bn ($3.87bn) a year more to buy medicines.
Following fresh criticism of the agency’s handling of the heparin case, in-PharmaTechnologist reports on a FDA official’s explanation of the what, the when and the why of the scandal, from first deaths to continued vigilance.